IKS014 in Advanced Solid Tumors That Express HER2

Summary

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

Timeline

Start

2023-09-14

Primary completion

2026-12

Completion

2027-12

Drugs

Indications